{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T18:09:31Z","timestamp":1791223771761,"version":"4.1.0"},"reference-count":46,"publisher":"American Society of Hematology","issue":"2","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2006,1,15]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Although most patients with cancer respond to therapy, few are cured. Moreover, objective clinical responses to treatment often do not even translate into substantial improvements in overall survival. For example, patients with indolent lymphoma who achieved a complete remission with conventional-dose therapies in the prerituximab era did not experience a survival advantage over similar patients treated with a \u201cwatch and wait\u201d approach. Several studies have also shown that neither the magnitude nor the kinetics of clinical response has an impact on survival in multiple myeloma. Recent data suggesting many malignancies arise from a rare population of cells that exclusively maintains the ability to self-renew and sustains the tumor (ie, \u201ccancer stem cells\u201d) may help explain this paradox that response and survival are not always linked. Therapies that successfully eliminate the differentiated cancer cells characterizing the tumor may be ineffective against rare, biologically distinct cancer stem cells. New methods for assessing treatment efficacy must also be developed, as traditional response criteria measure tumor bulk and may not reflect changes in rare cancer stem cell populations. In this article, we discuss the evidence for cancer stem cells in hematologic malignancies and possible ways to begin targeting these cells and measuring clinical effectiveness of such treatment approaches.<\/jats:p>","DOI":"10.1182\/blood-2005-06-2517","type":"journal-article","created":{"date-parts":[[2005,9,9]],"date-time":"2005-09-09T00:43:51Z","timestamp":1126226631000},"page":"431-434","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":121,"title":["The paradox of response and survival in cancer therapeutics"],"prefix":"10.1182","volume":"107","author":[{"given":"Carol Ann","family":"Huff","sequence":"first","affiliation":[{"name":"From the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Matsui","sequence":"additional","affiliation":[{"name":"From the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B. Douglas","family":"Smith","sequence":"additional","affiliation":[{"name":"From the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard J.","family":"Jones","sequence":"additional","affiliation":[{"name":"From the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2019111820274017200_REF1","doi-asserted-by":"crossref","unstructured":"Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92: 205-216.","DOI":"10.1093\/jnci\/92.3.205"},{"key":"2019111820274017200_REF2","doi-asserted-by":"crossref","unstructured":"Weir HK, Thun MJ, Hankey BF, et al. Annual report to the nation on the status of cancer, 1975-2000, featuring the uses of surveillance data for cancer prevention and control. J Natl Cancer Inst. 2003;95: 1276-1299.","DOI":"10.1093\/jnci\/djg040"},{"key":"2019111820274017200_","doi-asserted-by":"crossref","unstructured":"Jemal A, Clegg LX, Ward E, et al. Annual report to the nation on the status of cancer, 1975-2001, with a special feature regarding survival. Cancer. 2004;101: 3-27.","DOI":"10.1002\/cncr.20288"},{"key":"2019111820274017200_REF4","doi-asserted-by":"crossref","unstructured":"Burris HA, III, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997;15: 2403-2413.","DOI":"10.1200\/JCO.1997.15.6.2403"},{"key":"2019111820274017200_REF5","doi-asserted-by":"crossref","unstructured":"Pileri SA, Zinzani PL, Went P, Pileri A Jr, Bendandi M. Indolent lymphoma: the pathologist's viewpoint. Ann Oncol. 2004;15: 12-18.","DOI":"10.1093\/annonc\/mdh002"},{"key":"2019111820274017200_REF6","doi-asserted-by":"crossref","unstructured":"Horning SJ, Rosenberg SA. The natural history of initially untreated low-grade non-Hodgkin's lymphomas. N Engl J Med. 1984;311: 1471-1475.","DOI":"10.1056\/NEJM198412063112303"},{"key":"2019111820274017200_REF7","unstructured":"Horning SJ. Natural history of and therapy for the indolent non-Hodgkin's lymphomas. Semin Oncol. 1993;20: 75-88."},{"key":"2019111820274017200_REF8","doi-asserted-by":"crossref","unstructured":"Blade J, Lopez-Guillermo A, Bosch F, et al. Impact of response to treatment on survival in multiple myeloma: results in a series of 243 patients. Br J Haematol. 1994;88: 117-121.","DOI":"10.1111\/j.1365-2141.1994.tb04986.x"},{"key":"2019111820274017200_REF9","doi-asserted-by":"crossref","unstructured":"Durie BG, Jacobson J, Barlogie B, Crowley J. Magnitude of response with myeloma frontline therapy does not predict outcome: importance of time to progression in southwest oncology group chemotherapy trials. J Clin Oncol. 2004;22: 1857-1863.","DOI":"10.1200\/JCO.2004.05.111"},{"key":"2019111820274017200_REF10","doi-asserted-by":"crossref","unstructured":"Rocha Lima CM, Green MR, Rotche R, et al. Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine mono-therapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate. J Clin Oncol. 2004;22: 3776-3783.","DOI":"10.1200\/JCO.2004.12.082"},{"key":"2019111820274017200_REF11","doi-asserted-by":"crossref","unstructured":"Abratt RP, Brune D, Dimopoulos MA, et al. Randomised phase III study of intravenous vinorelbine plus hormone therapy versus hormone therapy alone in hormone-refractory prostate cancer. Ann Oncol. 2004;15: 1613-1621.","DOI":"10.1093\/annonc\/mdh429"},{"key":"2019111820274017200_REF12","doi-asserted-by":"crossref","unstructured":"Trump D, Lau YK. Chemotherapy of prostate cancer: present and future. Curr Urol Rep. 2003;4: 229-232.","DOI":"10.1007\/s11934-003-0074-3"},{"key":"2019111820274017200_REF13","doi-asserted-by":"crossref","unstructured":"Chung CT, Carlson RW. Goals and objectives in the management of metastatic breast cancer. Oncologist. 2003;8: 514-520.","DOI":"10.1634\/theoncologist.8-6-514"},{"key":"2019111820274017200_REF14","doi-asserted-by":"crossref","unstructured":"Fossella F, Pereira JR, von Pawel J, et al. Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group. J Clin Oncol. 2003;21: 3016-3024.","DOI":"10.1200\/JCO.2003.12.046"},{"key":"2019111820274017200_REF15","doi-asserted-by":"crossref","unstructured":"Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004;351: 1513-1520.","DOI":"10.1056\/NEJMoa041318"},{"key":"2019111820274017200_REF16","doi-asserted-by":"crossref","unstructured":"Jones RJ, Matsui WH, Smith BD. Cancer stem cells: are we missing the target? J Natl Cancer Inst. 2004;96: 583-585.","DOI":"10.1093\/jnci\/djh095"},{"key":"2019111820274017200_","doi-asserted-by":"crossref","unstructured":"Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature. 2001;414: 105-111.","DOI":"10.1038\/35102167"},{"key":"2019111820274017200_","doi-asserted-by":"crossref","unstructured":"Huntly BJ, Gilliland DG. Cancer biology: summing up cancer stem cells. Nature. 2005;435: 1169-1170.","DOI":"10.1038\/4351169a"},{"key":"2019111820274017200_REF19","doi-asserted-by":"crossref","unstructured":"Passegue E, Jamieson CH, Ailles LE, Weissman IL. Normal and leukemic hematopoiesis: are leukemias a stem cell disorder or a reacquisition of stem cell characteristics? Proc Natl Acad Sci U S A. 2003;100(suppl 1): 11842-11849.","DOI":"10.1073\/pnas.2034201100"},{"key":"2019111820274017200_REF20","doi-asserted-by":"crossref","unstructured":"Fialkow PJ, Gartler SM, Yoshida A. Clonal origin of chronic myelocytic leukemia in man. Proc Natl Acad Sci U S A. 1967;58: 1468-1471.","DOI":"10.1073\/pnas.58.4.1468"},{"key":"2019111820274017200_REF21","doi-asserted-by":"crossref","unstructured":"Bedi A, Zehnbauer BA, Collector MI, et al. BCR-ABL gene rearrangement and expression of primitive hematopoietic progenitors in chronic myeloid leukemia. Blood. 1993;81: 2898-2902.","DOI":"10.1182\/blood.V81.11.2898.2898"},{"key":"2019111820274017200_REF22","doi-asserted-by":"crossref","unstructured":"Matsui WH, Huff CA, Wang Q, et al. Characterization of clonogenic multiple myeloma cells. Blood. 2004;103: 2332-2336.","DOI":"10.1182\/blood-2003-09-3064"},{"key":"2019111820274017200_REF23","doi-asserted-by":"crossref","unstructured":"Lapidot T, Sirard C, Vormoor J, et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature. 1994;367: 645-648.","DOI":"10.1038\/367645a0"},{"key":"2019111820274017200_REF24","doi-asserted-by":"crossref","unstructured":"Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med. 1997;3: 730-737.","DOI":"10.1038\/nm0797-730"},{"key":"2019111820274017200_REF25","doi-asserted-by":"crossref","unstructured":"George AA, Franklin J, Kerkof K, et al. Detection of leukemic cells in the CD34(+)CD38(\u2013) bone marrow progenitor population in children with acute lymphoblastic leukemia. Blood. 2001;97: 3925-3930.","DOI":"10.1182\/blood.V97.12.3925"},{"key":"2019111820274017200_REF26","doi-asserted-by":"crossref","unstructured":"Nilsson L, Astrand-Grundstrom I, Anderson K, et al. Involvement and functional impairment of the CD34(+)CD38(\u2013)Thy-1(+) hematopoietic stem cell pool in myelodysplastic syndromes with trisomy 8. Blood. 2002;100: 259-267.","DOI":"10.1182\/blood-2001-12-0188"},{"key":"2019111820274017200_REF27","doi-asserted-by":"crossref","unstructured":"Al Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A. 2003;100: 3983-3988.","DOI":"10.1073\/pnas.0530291100"},{"key":"2019111820274017200_REF28","unstructured":"Singh SK, Clarke ID, Terasaki M, et al. Identification of a cancer stem cell in human brain tumors. Cancer Res. 2003;63: 5821-5828."},{"key":"2019111820274017200_REF29","doi-asserted-by":"crossref","unstructured":"Hemmati HD, Nakano I, Lazareff JA, et al. Cancerous stem cells can arise from pediatric brain tumors. Proc Natl Acad Sci U S A. 2003;100: 15178-15183.","DOI":"10.1073\/pnas.2036535100"},{"key":"2019111820274017200_REF30","doi-asserted-by":"crossref","unstructured":"NCCN. Chronic myelogenous leukemia clinical practice guidelines in oncology. J Natl Compr Canc Netw2003;1: 482-500.","DOI":"10.6004\/jnccn.2003.0041"},{"key":"2019111820274017200_REF31","doi-asserted-by":"crossref","unstructured":"O'Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003;348: 994-1004.","DOI":"10.1056\/NEJMoa022457"},{"key":"2019111820274017200_REF32","doi-asserted-by":"crossref","unstructured":"Cortes J, O'Brien S, Kantarjian H. Discontinuation of imatinib therapy after achieving a molecular response. Blood. 2004;104: 2204-2205.","DOI":"10.1182\/blood-2004-04-1335"},{"key":"2019111820274017200_REF33","unstructured":"Mauro MJ, Druker BJ, Kuyl J, Kurilik G, Maziarz RT. Increasing levels of detectable leukemia in imatinib treated CML patients with previously undetectable or very low levels of BCR-ABL [abstract]. Proc ASCO. 2003;22: 569."},{"key":"2019111820274017200_REF34","doi-asserted-by":"crossref","unstructured":"Graham SM, Jorgensen HG, Allan E, et al. Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood. 2002;99: 319-325.","DOI":"10.1182\/blood.V99.1.319"},{"key":"2019111820274017200_","doi-asserted-by":"crossref","unstructured":"Holtz MS, Slovak ML, Zhang F, et al. Imatinib mesylate (STI571) inhibits growth of primitive malignant progenitors in chronic myelogenous leukemia through reversal of abnormally increased proliferation. Blood. 2002;99: 3792-3800.","DOI":"10.1182\/blood.V99.10.3792"},{"key":"2019111820274017200_REF36","doi-asserted-by":"crossref","unstructured":"Angstreich GR, Matsui W, Huff CA, et al. Effects of imatinib and interferon on primitive chronic myeloid leukaemia progenitors. Br J Haematol. 2005;130: 373-381.","DOI":"10.1111\/j.1365-2141.2005.05606.x"},{"key":"2019111820274017200_REF37","doi-asserted-by":"crossref","unstructured":"Bonifazi F, de Vivo A, Rosti G, et al. Chronic myeloid leukemia and interferon-alpha: a study of complete cytogenetic responders. Blood. 2001;98: 3074-3081.","DOI":"10.1182\/blood.V98.10.3074"},{"key":"2019111820274017200_REF38","doi-asserted-by":"crossref","unstructured":"Pierce A, Smith DL, Jakobsen LV, Whetton AD, Spooncer E. The specific enhancement of interferon alpha induced growth inhibition by BCR\/ABL only occurs in multipotent cells. Hematol J. 2001;2: 257-264.","DOI":"10.1038\/sj.thj.6200114"},{"key":"2019111820274017200_REF39","doi-asserted-by":"crossref","unstructured":"Matsui W, Huff CA, Wang Q, et al. Multiple myeloma stem cells and plasma cells display distinct drug sensitivities [abstract]. Blood. 2004;104: 679a.","DOI":"10.1182\/blood.V104.11.2476.2476"},{"key":"2019111820274017200_REF40","doi-asserted-by":"crossref","unstructured":"Treon SP, Pilarski LM, Belch AR, et al. CD20-directed serotherapy in patients with multiple myeloma: biologic considerations and therapeutic applications. J Immunother. 2002;25: 72-81.","DOI":"10.1097\/00002371-200201000-00008"},{"key":"2019111820274017200_REF41","unstructured":"Mehrotra B, George TI, Kavanau K, et al. Cytogenetically aberrant cells in the stem cell compartment (CD34+lin-) in acute myeloid leukemia. Blood. 1995;86: 1139-1147."},{"key":"2019111820274017200_","doi-asserted-by":"crossref","unstructured":"Wittebol S, Raymakers R, van de LL, Mensink E, De Witte T. In AML t(8;21) colony growth of both leukemic and residual normal progenitors is restricted to the CD34+, lineage-negative fraction. Leukemia. 1998;12: 1782-1788.","DOI":"10.1038\/sj.leu.2401178"},{"key":"2019111820274017200_REF43","doi-asserted-by":"crossref","unstructured":"Blair A, Hogge DE, Sutherland HJ. Most acute myeloid leukemia progenitor cells with long-term proliferative ability in vitro and in vivo have the phenotype CD34(+)\/CD71(-)\/HLA-DR-. Blood. 1998;92: 4325-4335.","DOI":"10.1182\/blood.V92.11.4325"},{"key":"2019111820274017200_REF44","unstructured":"Uckun FM, Messinger Y, Chen CL, et al. Treatment of therapy-refractory B-lineage acute lymphoblastic leukemia with an apoptosis-inducing CD19-directed tyrosine kinase inhibitor. Clin Cancer Res. 1999;5: 3906-3913."},{"key":"2019111820274017200_REF45","doi-asserted-by":"crossref","unstructured":"Szatrowski TP, Dodge RK, Reynolds C, et al. Lineage specific treatment of adult patients with acute lymphoblastic leukemia in first remission with anti-B4-blocked ricin or high-dose cytarabine: Cancer and Leukemia Group B Study 9311. Cancer. 2003;97: 1471-1480.","DOI":"10.1002\/cncr.11219"},{"key":"2019111820274017200_REF46","doi-asserted-by":"crossref","unstructured":"Michor F, Hughes TP, Iwasa Y, et al. Dynamics of chronic myeloid leukaemia. Nature. 2005;435: 1267-1270.","DOI":"10.1038\/nature03669"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/107\/2\/431\/1280328\/zh800206000431.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/107\/2\/431\/1280328\/zh800206000431.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,17]],"date-time":"2021-07-17T06:31:26Z","timestamp":1626503486000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/107\/2\/431\/131452\/The-paradox-of-response-and-survival-in-cancer"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,1,15]]},"references-count":46,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2006,1,15]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2005-06-2517","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,1,15]]}}}